EANS-Adhoc: Marinomed Biotech AG / Marinomed determines IPO timelineand terms

Disclosed inside information pursuant to article 17 Market Abuse Regulation
(MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution.
The issuer is responsible for the content of this announcement.

Stock Offerings (IPO)
16.11.2018

Vienna – 16 November 2018. Marinomed Biotech AG has determined the timing and
terms of its initial public offering and listing on the Vienna Stock Exchange
(the „Offering“) today. The Offering will begin on Monday 19 November 2018 and
is expected to end on Thursday 29 November 2018, subject to the approval of the
prospectus by the Austrian Financial Market Authority (FMA) and the publication
of the prospectus, which are expected for today. The Offering comprises a public
offering to retail and institutional investors in Austria, a private placement
outside Austria to selected institutional investors, including a private
placement within the United States of America to qualified institutional buyers
in reliance on Rule 144A under the US Securities Act of 1933, as amended, and a
private placement outside of the United States of America to certain other
eligible institutional investors in reliance on Regulation S under the US
Securities Act of 1933, as amended. Any purchase orders received prior to the
commencement of a public offering will be rejected.

The Price Range for shares to be offered has been set at 75 to 90 Euro per
share. The final Offer Price is expected to be determined and announced on 29
November 2018. The expected settlement date and first trading day is 4 December
2018. From this date the Marinomed shares are intended to be traded under the
symbol „MARI“ on the official market (prime market segment) of the Vienna Stock
Exchange.

The Offering comprises up to 400,000 new bearer shares (base size), which may be
increased by up to 20% (the upsize option). In addition, the Offering may be
increased by up to a further 15% on top of the base size and the upsize option,
if any, through exercise of an over-allotment option (greenshoe option). The
gross proceeds of the Offering based on the Price Range will thus be between EUR
30 and 36 million (without exercise of the upsize and greenshoe option).

The proceeds from the Offering shall be used primarily to fund the Pivotal Phase
III study of Budesolv, Phase II and Phase III studies of Tacrosolv as well as
the extension of the Carragelose OTC platform.

The transaction meets the requirements of a qualified public offer in accordance
with the terms and conditions of the convertible bonds issued in 2017 that are
traded on the Third Market of the Vienna Stock Exchange. Following successful
completion of the Offering, convertible bondholders are expected to be entitled
from 4 December 2018 to convert their bonds into new shares of Marinomed Biotech
AG in accordance with the terms and conditions of the convertible bond (start of
conversion period, which, according to the terms and conditions of the
convertible bonds, lasts two weeks, hence until and including 18 December 2018).
The Conversion Price I (as defined in the terms and conditions of the
convertible bonds) to be adjusted on the basis of the final Offer Price is
expected to be determined and announced on 29 November 2018.

Marinomed Biotech AG reserves the right to premature termination or suspension
of the Offering, extension or shortening of the Offer Period.

About Marinomed Biotech AG
Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the
development of innovative products derived from patent protected technology
platforms to treat respiratory and ophthalmic conditions. The Carragelose®
platform comprises innovative patent protected products targeting viral
infections of the respiratory tract. Carragelose® is used in nasal sprays,
throat sprays and lozenges, which are sold in more than 30 countries around the
world in collaboration with international partners.The Marinosolv® technology
platform increases the efficacy of hardly soluble compounds for the treatment of
sensitive tissues such as the eyes and nose. Further information is available at
www.marinomed.com.

Disclaimer

This announcement does not constitute an offer to purchase securities or
solicitation of an offer to purchase securities in the United States of America,
Germany, Austria or other jurisdictions. The shares (the „Shares“) of Marinomed
Biotech AG (the „Company“) may only be sold or offered for sale after prior
registration in the United States of America upon or without prior registration
by virtue of an exemption from the registration requirement under the provisions
of the US Securities Act of 1933, as amended. The Company does not intend to
fully or partially register any offer of Shares in the United States or to make
any public offering of Shares in the United States.

A public offering of securities of the Company in Austria has not yet started
and shall be made solely by, and on the basis of, a prospectus for securities to
be prepared and published in accordance with the provisions of the Capital
Markets Act (Kapitalmarktgesetz) (including any supplements thereto). An
investment decision regarding publicly offered securities of the Company should
only be made on the basis of such a prospectus. Any purchase orders relating to
securities of the Company received prior to the commencement of a public
offering will be rejected. In connection with the proposed public offering of
securities of the Company in Austria, a prospectus prepared in accordance with
the provisions of the Capital Markets Act (Kapitalmarktgesetz) will be published
immediately upon approval by the Financial Market Authority
(Finanzmarktaufsicht) and be available free of charge at Marinomed Biotech AG,
Veterinärplatz 1, A-1210 Vienna, or on the website of Marinomed Biotech AG
(https://www.marinomed.com/offering).

end of announcement euro adhoc

issuer: Marinomed Biotech AG
Veterinärplatz 1
A-1210 Wien
phone: 0043250774460
FAX: 0043250774493
mail: office@marinomed.com
WWW: www.marinomed.com
ISIN: AT0000A1WD52
indexes:
stockmarkets: Wien
language: English

Digital press kit: http://www.ots.at/pressemappe/31479/aom

Eva Prieschl-Grassauer, PhD
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
Tel.: +43 (0)1 250 77 4460
E-mail: eva.prieschl@marinomed.com
http://www.marinomed.com
Roland Mayrl
Managing Partner, Metrum Communications
Prinz-Eugen-Straße 80/16, 1040 Vienna, Austria
Tel.: +43 (0) 1 504 69 87 331
E-mail: r.mayrl@metrum.at
http://www.metrum.at

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender